# reload+after+2024-01-20 03:32:44.716201
address1§520 Broad Street
city§Newark
state§NJ
zip§07102
country§United States
phone§212 658 1450
website§https://www.rafaelholdings.com
industry§Real Estate Services
sector§Real Estate
longBusinessSummary§Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
fullTimeEmployees§13
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Howard S. Jonas', 'age': 67, 'title': 'Founder & Executive Chairman', 'yearBorn': 1956, 'fiscalYear': 2023, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William  Conkling', 'age': 51, 'title': 'CEO & President', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 751949, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David A. Polinsky Esq.', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 363300, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Barbara A. Ryan', 'age': 63, 'title': 'Investor Relations Officer', 'yearBorn': 1960, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gus  Kodersha', 'title': 'Chief Technical Operations Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rick  Ewing', 'title': 'Head of Drug Discovery', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John Mayer Goldberg M.D.', 'age': 50, 'title': 'Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joyce J. Mason Esq.', 'age': 64, 'title': 'Corporate Secretary', 'yearBorn': 1959, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§9
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§168.09581
currency§USD
dateShortInterest§1702598400
exchange§NYQ
quoteType§EQUITY
shortName§Rafael Holdings, Inc.
longName§Rafael Holdings, Inc.
firstTradeDateEpochUtc§1522157400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c56da667-0419-3199-bc5f-75ba0a7e1338
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§14.827
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
